Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

Merck & Co has ended a second phase 3 trial ... Pharma has not given up the hunt for new drugs for Alzheimer’s – despite the setbacks a report by ResearchersAgainstAlzheimer’s last year ...

Merck & Co's earlier efforts to find new therapies for Alzheimer's disease resulted in failure, but the company is returning to the field via an R&D alliance with UK biotech Cerevance that will ...

Merck’s diabetes drugs – Januvia and Janumet – are likely to see increased competition. The company’s animal health business is likely to benefit from increased pet ownership in the U.S ...

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...

Merck CEO Rob Davis told CNBC's Jim Cramer that ... He also pointed to Winrevair, a medicine used to treat a rare and life-threatening lung condition that was approved by the Food and Drug ...